Alvotech Stock Price, News & Analysis

Alvotech (NASDAQ: ALVO), Kashiv Biosciences, and Advanz Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab). The biosimilar targets treatments for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps.

Xolair recorded global sales of $4.4 billion in 2024. The development builds on previous partnerships, including a February 2023 commercialization agreement between Alvotech and Advanz Pharma for AVT23, which was expanded in May 2023 to include five additional biosimilar candidates. Additionally, Alvotech and Kashiv established a licensing agreement for AVT23 in October 2023.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced plans to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm. The listing follows Alvotech's acquisition of Xbrane Biopharma's R&D operations and aims to expand its investor base in Nordic and European markets. The offering includes 441,600 SDRs with an estimated gross proceeds of SEK 30 million, with each SDR representing one share.

The offering price will be set at the lower of the volume-weighted average price or closing price of Alvotech shares on Nasdaq Iceland during the application period (May 9-16, 2025), with a 10% discount and capped at SEK 90 per SDR. Trading is expected to commence on May 19, 2025, under the ticker "ALVO SDB". Existing shareholders will have a one-year free conversion period to convert their shares into SDRs.

Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results with total revenues reaching $132.8M, up 260% year-over-year. Product revenues surged 786% to $109.9M, while achieving positive adjusted EBITDA of $20.5M compared to -$38.4M in 2023. The company increased its full-year guidance to $600-700M in revenue and $200-280M in adjusted EBITDA. Key highlights include the U.S. launch of SELARSDI (ustekinumab-aekn), a Stelara biosimilar, and BLA filing acceptances for biosimilars to Simponi/Simponi Aria, Eylea, and Prolia/Xgeva. Alvotech acquired Xbrane's R&D operations and rights to a Cimzia biosimilar. The company reported a net profit of $109.7M ($0.39 per share) and expects to be free cash-flow positive in 2025.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in biosimilar medicines, has announced that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on its 2025 product revenues. The company, which manufactures its biosimilars in Iceland, faces a minimum 10% tariff on U.S. imports. This tariff would increase costs for U.S. customers by less than 1% of Alvotech's expected 2025 product revenues.

According to contracted terms, customers are responsible for transport costs and import duties, not Alvotech. CEO Robert Wessman noted that Iceland's favorable trade balance with the U.S. makes higher tariffs unlikely, and emphasized that biosimilars remain the most cost-effective way to increase patient access to vital biologics. Beyond 2025, even with anticipated product launches and increased sales, the tariff impact would still represent a low single-digit percentage of total product revenues.

Alvotech (NASDAQ: ALVO), a global biotech company, announced the acquisition of Xbrane Biopharma AB's R&D operations and biosimilar candidate XB003 for approximately SEK 275 million (USD 27 million). The deal includes Xbrane's R&D operations at Campus Solna, Karolinska Institute, and will be paid through SEK 102.2 million in cash and SEK 172.8 million in debt assumption. Xbrane retains pre-clinical assets and will focus on commercialization. The acquisition strengthens Alvotech's development capabilities and establishes presence in Sweden's life science sector. Alvotech plans to explore listing Swedish Depository Receipts on Nasdaq Stockholm. The deal, expected to close in April 2025, is supported by Xbrane's Board and key shareholders. Since 2013, Alvotech has invested $1.9 billion in biosimilars R&D and manufacturing, partnering with 19 companies across 90 global markets.

The FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara® (ustekinumab) for all presentations, as announced by Teva Pharmaceuticals (TEVA) and Alvotech (ALVO). The approval, effective April 30, 2025, covers treatments for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in various age groups. SELARSDI is available in multiple presentations including 45 mg/0.5 mL and 90 mg/mL prefilled syringes, and other formulations. This marks the second successful biosimilar launch under the Teva-Alvotech partnership, following SIMLANDI®. The companies have three additional biosimilar candidates under FDA review, with BsUFA goal dates in Q4 2025.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on May 7, 2025, followed by an analyst conference call on May 8, 2025, at 8:00 am EDT (14:00 CET).

The conference call will be accessible via webcast to media, investors, and the public through Alvotech's investor website. The webcast recording will remain available for replay for 90 days after the event.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on Wednesday, May 7, 2025.

A conference call with analysts to discuss financial results and recent business highlights will be held on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). The event will be accessible via webcast through Alvotech's investor website, with a 90-day replay period available after the presentation.

Teva Pharmaceuticals and Alvotech have announced the U.S. launch of SELARSDI™, their second biosimilar under their strategic partnership. SELARSDI, a biosimilar to Stelara® (ustekinumab), received FDA approval in October 2024 for treating multiple conditions including psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis in both adults and children.

The FDA has provisionally determined SELARSDI's interchangeability with Stelara® following April 30, 2025. The drug is available in four presentations matching Stelara's approved formats. This launch follows their first biosimilar SIMLANDI®, approved in February 2024 and launched in May 2024.

Under the partnership, Alvotech handles development and manufacturing, while Teva manages U.S. commercialization. Their collaboration, initiated in August 2020, now covers seven biosimilar products.